A股異動 | 香雪製藥(300147.SZ)續漲逾7% 公司板藍根庫存已清空
格隆匯10月19日丨香雪製藥(300147.SZ)股價衝高回落,盤中最高見14.48元,最大漲幅近12%,現報13.88元,漲幅7.68%,最新總市值92億,換手率17%;該股上交易日漲停。公司中藥產品包括抗病毒口服液、板藍根顆粒等。此前,鍾南山團隊表示,體外研究發現白雲山複方板藍根對新冠病毒有效。香雪製藥營銷負責人17日稱,目前,公司板藍根庫存已經清空,提貨需求較平時出現大幅增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.